# A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants

> **NCT06612970** · PHASE1 · RECRUITING · sponsor: **Shanghai Huaota Biopharmaceutical Co., Ltd.** · enrollment: 46 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HB0056
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06612970
- **Lead sponsor:** Shanghai Huaota Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-18
- **Primary completion:** 2025-06-13
- **Final completion:** 2025-10-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06612970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06612970, "A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06612970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*